B. Braun Receives FDA 510(k) Clearance for New DUPLEX System Use

B. Braun has received FDA 510(k) clearance for adding 1 gram and 2 gram Ceflazidime injections within the DUPLEX System, according to a company news release.

Advertisement

The clearance has expanded the number of intravenous therapies the system supports. The 1 and 2 gram Ceflazidime injections can be stored in the DUPLEX System and ready-to-use whenever and wherever it is needed. The DUPLEX System is designed as a two-comparement, flexible, eco-friendly IV container to store pre-measured drug and diluent doses.

Read the release about the new clearance for B. Braun.

More Coverage on B. Braun:

B. Braun Receives Permanent Injunction in Patent Infringement Case

B. Braun Reports 9.8% Sales Growth for FY 2010

B. Braun Announces FDA Approval of OTC Wound Management Gel

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.